Q-omics provides the consensus-scored CCDC122 profile across patient tissues and cancer cell-line models. CCDC122 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, CCDC122 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, CCDC122 RNA expression shows 19,933 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LGG, KICH, and UVM as cancer lineages where CCDC122 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC122 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC122 survival associations across molecular data types. CCDC122 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC122 RNA expression–survival associations across cancer types. High CCDC122 expression shows unfavorable associations in LGG and UVM, but favorable associations in KIRP, COAD, PAAD and KIRC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for CCDC122 RNA expression.
This table summarizes CCDC122 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC122. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC122 shows lower tumor expression in KICH, THCA and BRCA and higher tumor expression in HNSC, CHOL and LIHC. The KICH box plot shows higher CCDC122 RNA expression in normal versus tumor tissue (log2 FC = −1.172, t-test p < 0.001).
This table shows molecular features associated with CCDC122 in patient tissues and cancer cell lines. In patient samples, CCDC122 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC122 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
